Premium
Adjuvant treatment to radiation: combined hormone therapy and external radiotherapy for locally advanced prostate cancer
Author(s) -
Bolla Michel,
Descotes JeanLuc,
Artignan Xavier,
Fourneret Philippe
Publication year - 2007
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/j.1464-410x.2007.06954.x
Subject(s) - medicine , radiation oncology , prostate cancer , university hospital , radiation therapy , adjuvant radiotherapy , oncology , cancer
The main phase III trials studying the benefit of HT using an LHRH analogue with or without antiandrogen were conducted by the Radiation Therapy Oncology Group (RTOG), the European Organization for Research and Treatment of Cancer (EORTC), and the TransTasman Radiation Oncology Group (TTROG) (Table 1). In the Early Prostate Cancer (EPC) trial programme, the effect of antiandrogen adjuvant to RT was studied in patients receiving standard care, including those receiving RT.